TRCT
VRPX

Tower Research Capital (TRC)’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Tower Research Capital (TRC)’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,897
Closed -$5.88K – 5697
2025
Q1 		$5.88K Buy
4,897
+4,587
+1,480% +$28.1K ﹤0.01% 4081
2024
Q4 		$2.95K Buy
310
+157
+103% +$2.09K ﹤0.01% 4742
2024
Q3 		$2.66K Buy
153
+27
+21% +$670 ﹤0.01% 4953
2024
Q2 		$1.63K Buy
126
+68
+117% +$3.32K ﹤0.01% 5123
2024
Q1 		$6.17K Buy
58
+33
+132% +$2.9K ﹤0.01% 4420
2023
Q4 		$2.02K Hold
25
– – ﹤0.01% 5287
2023
Q3 		$4.98K Buy
25
+3
+14% +$661 ﹤0.01% 4781
2023
Q2 		$5.87K Hold
22
– – ﹤0.01% 4781
2023
Q1 		$4K Buy
22
+1
+5% +$223 ﹤0.01% 5139
2022
Q4 		$3K Buy
21
+3
+17% +$683 ﹤0.01% 5281
2022
Q3 		$5K Buy
18
+8
+80% +$2.88K ﹤0.01% 5192
2022
Q2 		$4K Buy
+10
New +$4.1K ﹤0.01% 5290
2022
Q1 		– Sell
-3
Closed -$2K – 6759
2021
Q4 		$2K Buy
+3
New +$3.09K ﹤0.01% 5707

Other funds holding VRPX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Tower Research Capital (TRC)'s VRPX Position: Q2 2025 in Review

Tower Research Capital (TRC) sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q2 2025, closing a stake of 4,897 shares — an estimated $5.88K sold.

Tower Research Capital (TRC) first reported a position in VRPX in Q4 2021 and held it in 13 quarters. The position peaked at $6.17K in Q1 2024. 1 fund tracked by Wall St. Rank holds VRPX as of Q2 2025.

  • Tower Research Capital (TRC) reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 4,897 Virpax Pharmaceuticals, Inc. Common Stock shares in Q2 2025, an estimated $5.88K.
  • Tower Research Capital (TRC) first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 13 quarters.
  • Tower Research Capital (TRC)'s Virpax Pharmaceuticals, Inc. Common Stock position peaked at $6.17K in Q1 2024.
  • 1 fund tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q2 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.